Analysts Offer Insights on Healthcare Companies: Impedimed Limited (OtherIPDQF) and Mach7 Technologies (OtherTDMMF)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Impedimed Limited (IPDQF – Research Report) and Mach7 Technologies (TDMMF – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Impedimed Limited (IPDQF)
In a report released today, Scott Power from Morgans maintained a Buy rating on Impedimed Limited, with a price target of A$0.15. The company's shares closed last Thursday at $0.04.
Power has an average return of 14.0% when recommending Impedimed Limited.
According to TipRanks.com, Power is ranked #8478 out of 9504 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Impedimed Limited with a $0.08 average price target, an 113.9% upside from current levels. In a report issued on April 30, Canaccord Genuity also maintained a Buy rating on the stock with a A$0.09 price target.
Morgans analyst Iain Wilkie maintained a Buy rating on Mach7 Technologies today and set a price target of A$1.37. The company's shares closed last Tuesday at $0.24, equals to its 52-week low of $0.24.
According to TipRanks.com, Wilkie is ranked #8787 out of 9504 analysts.
Mach7 Technologies has an analyst consensus of Strong Buy, with a price target consensus of $0.65, representing a 170.8% upside. In a report issued on April 30, Wilsons also maintained a Buy rating on the stock with a A$0.85 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
Macquarie Remains a Buy on Steadfast Group Limited (1S6)
In a report released today, from Macquarie maintained a Buy rating on Steadfast Group Limited (1S6 – Research Report), with a price target of A$6.80. The company's shares closed last Friday at €3.24. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Currently, the analyst consensus on Steadfast Group Limited is a Strong Buy with an average price target of €3.81. Based on Steadfast Group Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €931.5 million and a net profit of €106.4 million. In comparison, last year the company earned a revenue of €804.7 million and had a net profit of €100.4 million
Business Insider
31 minutes ago
- Business Insider
Petra Capital Sticks to Their Buy Rating for Iperionx Limited (IPX)
In a report released on June 6, Hugh Stackpool from Petra Capital maintained a Buy rating on Iperionx Limited (IPX – Research Report), with a price target of A$8.21. The company's shares closed today at A$4.15. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Stackpool is ranked #9428 out of 9593 analysts. Iperionx Limited has an analyst consensus of Strong Buy, with a price target consensus of A$6.62, implying a 59.52% upside from current levels. In a report released on June 5, Bell Potter also maintained a Buy rating on the stock with a A$6.25 price target. IPX market cap is currently A$1.41B and has a P/E ratio of -26.39. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IPX in relation to earlier this year.
Business Insider
31 minutes ago
- Business Insider
Morgan Stanley Remains a Buy on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX)
In a report released today, James Bales from Morgan Stanley maintained a Buy rating on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX – Research Report), with a price target of A$32.00. The company's shares closed last Thursday at $18.92. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bales is an analyst with an average return of -0.6% and a 39.85% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Corporate Travel Management Limited, Flight Centre Travel Group Limited, and WEB Travel Group. Currently, the analyst consensus on Life360 Shs Chess Depository Interests Repr 3 Sh is a Strong Buy with an average price target of $19.72. The company has a one-year high of $23.00 and a one-year low of $8.65. Currently, Life360 Shs Chess Depository Interests Repr 3 Sh has an average volume of 3,215.
